Cited by 2,527Lung Cancer Treatments and MutationsLung Cancer Research StudiesLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer

Open access

Peters, Solange, Camidge, D. Ross, Shaw, Alice T., Gadgeel, Shirish, Ahn, Jin S., Kim, Dong-Wan, Ou, Sai-Hong I., Pérol, Maurice, Dziadziuszko, Rafal, Rosell, Rafael, Zeaiter, Ali, Mitry, Emmanuel, Golding, Sophie, Balas, Bogdana, Noe, Johannes, Morcos, Peter N., Mok, Tony·2017·New England Journal of Medicine

DOI 10.1056/nejmoa1704795

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive non-small-cell lung cancer (NSCLC). We investigated alectinib as compared with crizotinib in patients with previously untreated, advanced ALK-positive NSCLC, including those with asymptomatic CNS disease. METHODS: In a randomized, open-label, phase 3 trial, we randomly assigned 303 patients with previously untreated, advanced ALK-positive NSCLC to receive either alectinib (600 mg twice daily) or crizotinib (250 mg twice daily). The primary end point was investigator-assessed progression-free survival. Secondary end points were independent review committee-assessed progression-free survival, time to CNS progression, objective response rate, and overall survival. RESULTS: During a median follow-up of 17.6 months (crizotinib) and 18.6 months (alectinib), an event of disease progression or death occurred in 62 of 152 patients (41%) in the alectinib group and 102 of 151 patients (68%) in the crizotinib group. The rate of investigator-assessed progression-free survival was significantly higher with alectinib than with crizotinib (12-month event-free survival rate, 68.4% [95% confidence interval (CI), 61.0 to 75.9] with alectinib vs. 48.7% [95% CI, 40.4 to 56.9] with crizotinib; hazard ratio for disease progression or death, 0.47 [95% CI, 0.34 to 0.65]; P<0.001); the median progression-free survival with alectinib was not reached. The results for independent review committee-assessed progression-free survival were consistent with those for the primary end point. A total of 18 patients (12%) in the alectinib group had an event of CNS progression, as compared with 68 patients (45%) in the crizotinib group (cause-specific hazard ratio, 0.16; 95% CI, 0.10 to 0.28; P<0.001). A response occurred in 126 patients in the alectinib group (response rate, 82.9%; 95% CI, 76.0 to 88.5) and in 114 patients in the crizotinib group (response rate, 75.5%; 95% CI, 67.8 to 82.1) (P=0.09). Grade 3 to 5 adverse events were less frequent with alectinib (41% vs. 50% with crizotinib). CONCLUSIONS: As compared with crizotinib, alectinib showed superior efficacy and lower toxicity in primary treatment of ALK-positive NSCLC. (Funded by F. Hoffmann-La Roche; ALEX ClinicalTrials.gov number, NCT02075840 .).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1704795

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Self-citation
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK -Rearranged Lung Cancer
Gainor, J. F., Dardaei, L., Yoda, S., Friboulet, L., Leshchiner, I., Katayama, R., Dagogo‐Jack, I., Gadgeel, S. M., Schultz, K. R., Singh, M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0596 · Cited by 1,180
Self-citation
First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Soria, J.-C., Tan, D. S. W., Chiari, R., Wu, Y.-L., Paz-Ares, L., Wolf, J., Geater, S. L., Orlov, S., Cortinovis, D., Yu, C.-J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30123-x · Cited by 1,151
Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
Hida, T., Nokihara, H., Kondo, M., Kim, Y. H., Azuma, K., Seto, T., Takiguchi, Y., Nishio, M., Yoshioka, H., Imamura, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30565-2 · Cited by 935
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
Gadgeel, S. M., Gandhi, L., Riely, G. J., Chiappori, A., West, H., Azada, M. C., Morcos, P. N., Lee, R.-M., Garcia, L., Yu, L. J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70362-6 · Cited by 709
Self-citation
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
Shaw, A. T., Gandhi, L., Gadgeel, S., Riely, G. J., Cetnar, J., West, H., Camidge, D. R., Socinski, M. A., Chiappori, A., Mekhail, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00488-x · Cited by 638
Self-citation
Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study
Ou, S. I., Ahn, J. S., Petris, L. D., Govindan, R., Yang, J. C., Hughes, B. G. M., Léna, H., Moro‐Sibilot, D., Bearz, A., Viteri, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.9443 · Cited by 592
Self-citation
Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers
Rangachari, D., Yamaguchi, N., VanderLaan, P. A., Folch, E. E., Mahadevan, A., Floyd, S., Uhlmann, E. J., Wong, E. T., Dahlberg, S. E., Huberman, M. S., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.01.020 · Cited by 547
Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine
Katayama, R., Lovly, C. M., & Shaw, A. T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2791 · Cited by 265
Self-citation
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
Awad, M. M., & Shaw, A. T. (2014) · PubMed · Cited by 245
Self-citation

Flagged first, then by citations

Show all 14 references

Research works printed but not linked: 3

Awad MM, 2014, Clin Adv Hematol Oncol, 12, 429
Lu S, 2016, J Clin Oncol
Hida T, Lancet

Sorted by citations

Items 901–1,000 of 1,000

Advances in Targeted Therapy for Non-Small-Cell Lung Cancer: Current Progress and Future Directions
Peshin, S., Takrori, E., Yazji, J. H., Haque, J., Dharia, A. A., Mithani, M. S., Anum, F., Asfeen, U. Z., Couch, J. K., Donovan, M., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311517 · Cited by 15
Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung
Jang, Y. J., Hyun, D., Choi, C., Lee, K. H., Kim, S., Yoon, S., Kim, W. S., Ji, W., & Lee, J. C. (2021) · BMC Cancer · doi:10.1186/s12885-021-08472-6 · Cited by 14
PI3Kβ inhibition enhances ALK ‐inhibitor sensitivity in ALK ‐rearranged lung cancer
Talwelkar, S. S., Mäyränpää, M. I., Schüler, J. B., Linnavirta, N., Hemmes, A., Adinolfi, S., Kankainen, M., Sommergruber, W., Levonen, A., Räsänen, J. V., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13342 · Cited by 14
Alectinib-Induced Severe Hemolytic Anemia in a Patient with ALK-Positive Non-Small Cell Lung Cancer: A Case Report
Misawa, K., Nakamichi, S., Iida, H., Nagano, A., Mikami, E., Tozuka, T., Matsumoto, M., Miyanaga, A., Noro, R., Kubota, K., et al. (2023) · OncoTargets and Therapy · doi:10.2147/ott.s398375 · Cited by 14
Detecting ALK , ROS1 , and RET fusions and the METΔex14 splicing variant in liquid biopsies of non‐small‐cell lung cancer patients using RNA ‐based techniques
Giménez-Capitán, A. A., Sánchez‐Herrero, E., de Lope, L. R., Aguilar‐Hernández, A., Sullivan, I., Calvo, V., Moya‐Horno, I., Viteri, S., Cabrera, C., Aguado, C., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13468 · Cited by 14
Self-citation
Prognostic Factors and Markers in Non-Small Cell Lung Cancer: Recent Progress and Future Challenges
Meira, D. D., Caetano, M. C. D. C. E., Casotti, M. C., Zetum, A. S. S., Gonçalves, A. F. M., Moreira, A. R., de Oliveira, A. H., Pesente, F., Santana, G. M., Duque, D. D. A., et al. (2023) · Genes · doi:10.3390/genes14101906 · Cited by 14
Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue Sarcomas Using DNA/RNA-based Clinical Sequencing
Hasegawa, N., Hayashi, T., Niizuma, H., Kikuta, K., Imanishi, J., Endo, M., Ikeuchi, H., Sasa, K., Sano, K., Hirabayashi, K., et al. (2023) · Clinical Orthopaedics and Related Research · doi:10.1097/corr.0000000000002901 · Cited by 14
Combinatorial Approaches for Chemotherapies and Targeted Therapies With Radiation: United Efforts to Innovate in Patient Care
Jabbour, S. K., Kumar, R. N., Anderson, B. M., Chino, J., Jethwa, K. R., McDowell, L. J., Lo, A., Owen, D., Pollom, E. L., Tree, A. C., et al. (2024) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2024.01.010 · Cited by 14
Navigating the Complexities of Brain Metastases Management
Amouzegar, A., Haig, S., Kahn, A. M., Tawbi, H. A., Jones, J., & Goldberg, S. B. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_433694 · Cited by 15
Single-cell EpiChem jointly measures drug–chromatin binding and multimodal epigenome
Dong, C. F., Meng, X., Zhang, T., Guo, Z., Liu, Y., Wu, P., Chen, S., Zhou, F., Ma, Y., Xiong, H., et al. (2024) · Nature Methods · doi:10.1038/s41592-024-02360-0 · Cited by 17
Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario
Fuorivia, V., Attili, I., Corvaja, C., Asnaghi, R., Schianca, A. C., Aliaga, P. T., Signore, E. D., Spitaleri, G., Passaro, A., & de Marinis, F. (2024) · Current Oncology · doi:10.3390/curroncol31090379 · Cited by 15
Safety of solid oncology drugs in older patients: a narrative review
Rousseau, A., Géraud, A., Geiss, R., Farcet, A., Spano, J., Hamy, A., & Gougis, P. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103965 · Cited by 14
Oligometastatic NSCLC: Current Perspectives and Future Challenges
Torresan, S., Costa, J., Zanchetta, C., Marchi, L. D., Rizzato, S., & Cortiula, F. (2025) · Current Oncology · doi:10.3390/curroncol32020075 · Cited by 14
Anaplastic lymphoma kinase (ALK)-rearranged pulmonary pleomorphic carcinoma successfully treated with crizotinib
Lin, L., Huang, F., Chen, F., He, Y., Hu, J., & Cao, X. (2018) · Journal of International Medical Research · doi:10.1177/0300060517748262 · Cited by 14
Prolonged Leptomeningeal Responses with Brigatinib in Two Heavily Pretreated ALK-Rearranged Non–Small Cell Lung Cancer Patients
Géraud, A., Mezquita, L., Bigot, F., Caramella, C., Planchard, D., Pechoux, C. L., & Besse, B. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.033 · Cited by 14
Central nervous system relapse of systemic ALK-rearranged anaplastic large cell lymphoma treated with alectinib
Tomlinson, S. B., Sandwell, S. E., Chuang, S. T., Johnson, M. D., Vates, G. E., & Reagan, P. M. (2019) · Leukemia Research · doi:10.1016/j.leukres.2019.05.014 · Cited by 14
Elucidating synergistic dependencies in lung adenocarcinoma by proteome-wide signaling-network analysis
Bansal, M., He, J., Peyton, M., Kustagi, M., Iyer, A., Comb, M. J., White, M. A., Minna, J. D., & Califano, A. (2019) · PLoS ONE · doi:10.1371/journal.pone.0208646 · Cited by 14
Differences Between the East and the West in Managing Advanced-Stage Non-small Cell Lung Cancer
Lee, V. H.-F., Mok, T. S. K., Goto, Y., Hsue, V. C. C., Li, Y., Jiang, Y., Leung, D. K. C., Lau, K. S., & Tse, P. Y. H. (2019) · Clinical Oncology · doi:10.1016/j.clon.2019.07.014 · Cited by 14
Self-citation
The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4–ALK Rearranged Non-small Cell Lung Cancer
Lin, Y., Liu, Y., & Shih, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00880 · Cited by 14
Analysis of key clinical features for achieving complete remission in stage III and IV non-small cell lung cancer patients
Aoki, T., Akiba, T., Nishiyama, J., Tajiri, S., Hayama, N., Takahashi, G., Tanaka, J., Sato, M., Takiguchi, H., Tomomatsu, H., et al. (2019) · Respiratory Research · doi:10.1186/s12931-019-1235-3 · Cited by 14
Percutaneous CT-guided biopsy of lytic bone lesions in patients clinically suspected of lung cancer: Diagnostic performances for pathological diagnosis and molecular testing
Toffart, A., Asfari, S., Leer, A. M., Reymond, É., Jankowski, A., Moro‐Sibilot, D., Stephanov, O., Ghelfi, J., Lantuéjoul, S., & Ferretti, G. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.12.012 · Cited by 14
Optimal Management of Patients with Advanced NSCLC Harboring High PD-L1 Expression and Driver Mutations
Chen, J. A., & Riess, J. W. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00750-y · Cited by 14
Serum CEA and CYFRA Levels in ALK-rearranged NSCLC Patients: Correlation With Distant Metastasis
Numata, T., Endo, T., Yanai, H., Ota, K., Yamamoto, Y., Shimizu, K., Yamada, H., Hayashihara, K., Okauchi, S., Satoh, H., et al. (2020) · In Vivo · doi:10.21873/invivo.12013 · Cited by 14
Anaplastic lymphoma kinase (ALK) rearrangement in adult renal cell carcinoma with lung metastasis: a case report and literature review
Zhou, S., Sun, G., Wang, J., & Zhang, H. (2020) · Translational Andrology and Urology · doi:10.21037/tau-20-1343 · Cited by 15
Accurate genotyping of fragmented DNA using a toehold assisted padlock probe
Gao, Y., Qiao, H., Pan, V., Wang, Z., Li, J., Wei, Y., Ke, Y., & Qi, H. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113079 · Cited by 14
ALTA-2: Phase II Study of Brigatinib in Patients with ALK-Positive, Advanced Non-Small-Cell Lung Cancer Who Progressed on Alectinib or Ceritinib
Kim, E. S., Barlési, F., Mok, T. S. K., Ahn, M., Shen, J., Zhang, P., & Ou, S. I. (2021) · Future Oncology · doi:10.2217/fon-2020-1119 · Cited by 14
Self-citation
Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer
Sun, F., & McCoach, C. E. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00867-8 · Cited by 14
STRN-ALKFusion in a Case of Malignant Peritoneal Mesothelioma: Mixed Response to Crizotinib, Mode of Resistance, and Brigatinib Sequential Therapy
Gerthofer, V., Scheiter, A., Lüke, F., Keil, F., Utpatel, K., Pöhmerer, L., Seitz, J., Niessen, C., Ignatov, A., Dietmaier, W., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00184 · Cited by 14
TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer
Lü, J., Zhong, R., Lou, Y., Hu, M., Yang, Z., Wang, Y., Chen, Y., Zou, B., Zhang, W., Wang, H., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.732125 · Cited by 14
The economic impact of compassionate use of medicines
Jommi, C., Pantellini, F., Stagi, L., Verykiou, M., & Cavazza, M. (2021) · BMC Health Services Research · doi:10.1186/s12913-021-07255-w · Cited by 14
Thoracic neoplasms
Krzakowski, M. J., Jassem, J., Antczak, A. J., Błasińska, K., Chorostowska‐Wynimko, J., Dziadziuszko, R., Głogowski, M., Grodzki, T., Kowalski, D. R., Krenke, R., et al. (2022) · Oncology in Clinical Practice · doi:10.5603/ocp.2021.0022 · Cited by 16
Self-citation
Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy
Bodor, J. N., Bauman, J. R., Handorf, E. A., Ross, E. A., Clapper, M. L., & Treat, J. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04089-9 · Cited by 14
Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations
Canale, M., Petracci, E., Cravero, P., Mariotti, M., Minuti, G., Metro, G., Ludovini, V., Baglivo, S., Puccetti, M., Dubini, A., et al. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101471 · Cited by 16
Lorlatinib as a treatment for ALK-positive lung cancer
Baba, K., & Goto, Y. (2022) · Future Oncology · doi:10.2217/fon-2022-0184 · Cited by 14
Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)
Watanabe, S., Sakai, K., Matsumoto, N., Koshio, J., Ishida, A., Abe, T., Ishikawa, D., Tanaka, T., Aoki, A., Kajiwara, T., et al. (2022) · Cancers · doi:10.3390/cancers15010204 · Cited by 14
Precision Surgery in NSCLC
Cannone, G., Comacchio, G. M., Pasello, G., Faccioli, E., Schiavon, M., Dell’Amore, A., Mammana, M., & Rea, F. (2023) · Cancers · doi:10.3390/cancers15051571 · Cited by 14
First-Line Alectinib vs. Brigatinib in Advanced Non–Small Cell Lung Cancer with ALK Rearrangement: Real-World Data
Jeon, Y., Park, S., Jung, H. A., Sun, J., Lee, S., Ahn, J. S., & Ahn, M. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2023.461 · Cited by 14
Self-citation
Expression Differentiation Is Not Helpful in Identifying Prognostic Genes Based on TCGA Datasets
An, N., Yu, Z., & Yang, X. C. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.02.013 · Cited by 14
Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines
Chen, Y., Ma, G., Su, C., Wu, P., Wang, H., Song, X., Yu, Q., Zeng, A., & Zhou, S. (2018) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000667 · Cited by 14
Lorlatinib: a new-generation drug for ALK-positive NSCLC
Waqar, S. N., & Morgensztern, D. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30789-7 · Cited by 14
Meta-analysis of overall incidence and risk of ALK inhibitors-induced liver toxicities in advanced non-small-cell lung cancer
Li, J., Yuan, Z., Wang, Q., Fan, W., & Zhang, G. (2019) · Medicine · doi:10.1097/md.0000000000013726 · Cited by 15
Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase‐Positive Non‐Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat
Hohmann, N., Bozorgmehr, F., Christopoulos, P., Mikus, G., Blank, A., Burhenne, J., Thomas, M., & Haefeli, W. E. (2020) · Clinical and Translational Science · doi:10.1111/cts.12921 · Cited by 14
Prospective Multicenter Validation of the Detection of ALK Rearrangements of Circulating Tumor Cells for Noninvasive Longitudinal Management of Patients With Advanced NSCLC
Ilié, M., Mazières, J., Chamorey, E., Heeke, S., Benzaquen, J., Thamphya, B., Boutros, J., Tiotiu, A. I., Fayada, J., Cadranel, J. L., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.01.1617 · Cited by 14
Targeted Therapies in Older Adults With Solid Tumors
Battisti, N. M. L., Decoster, L., Williams, G. R., Kanesvaran, R., Wildiers, H., & Ring, A. E. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00132 · Cited by 14
Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial
Solomon, B., Dagogo‐Jack, I., Lee, S.-H., Boyer, M. J., Ramalingam, S. S., Carcereny, E., Felip, E., Han, J., Hida, T., Hughes, B. G. M., et al. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100685 · Cited by 14
Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM)
Facchinetti, F., Pilotto, S., Metro, G., Baldini, E., Bertolaccini, L., Cappuzzo, F., Delmonte, A., Gasparini, S., Inno, A., Marchetti, A., et al. (2019) · Tumori Journal · doi:10.1177/0300891619857418 · Cited by 14
Fibroblasts and Alectinib switch the evolutionary games played by non-small cell lung cancerPreprint
Kaznatcheev, A., Peacock, J., Basanta, D., Marusyk, A., & Scott, J. G. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/179259 · Cited by 14
MatchMiner: An open source computational platform for real-time matching of cancer patients to precision medicine clinical trials using genomic and clinical criteriaPreprint
Lindsay, J. R., Fitz, C. D. V., Zwiesler, Z., Kumari, P., Veen, B. V. D., Monrose, T., Mazor, T., Barry, S., Albayrak, A., Tung, M., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/199489 · Cited by 14
50 Years of Progress in NSCLC: A New Fellow’s Guide in the Clinic
Naidoo, J., Niroula, A., Uprety, D., Smeltzer, M. P., Geissen, N. M., Osarogiagbon, R. U., Mino-Kenudson, M. A., Yatabe, Y., Higgins, K. A., Desai, A. P., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.06.028 · Cited by 13
Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies
Malik, P., Rani, R., Solanki, R., Patel, V. H., & Mukherjee, T. K. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00171 · Cited by 14
Concurrent inhibition of ALK and SRC kinases disrupts the ALK lung tumor cell proteome
Diaz-Jimenez, A., Ramos, M., Helm, B., Chocarro, S., Frey, D. L., Agrawal, S., Somogyi, K., Klingmüller, U., Lu, J., & Sotillo, R. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101081 · Cited by 14
Understanding the treatment response and resistance to targeted therapies in non-small cell lung cancer: clinical insights and perspectives
Zhang, H., Zhang, Y., Zhu, Y., Dong, T., & Liu, Z. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1387345 · Cited by 14
Optimization of treatment strategies for elderly patients with advanced non-small cell lung cancer
Chen, Q., Ying, S., Qin, J., & Zhang, L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1384906 · Cited by 14
Resistance in Lung Cancer Immunotherapy and How to Overcome It: Insights from the Genetics Perspective and Combination Therapies Approach
Zieliński, P., Stępień, M., Chowaniec, H., Kalyta, K., Czerniak, J., Borowczyk, M., Dwojak, E., Mroczek, M., Dworacki, G., Ślubowska, A., et al. (2025) · Cells · doi:10.3390/cells14080587 · Cited by 14
Cannabidiol potentiates p53-driven autophagic cell death in non-small cell lung cancer following DNA damage: a novel synergistic approach beyond canonical pathways
Jeon, Y., Kim, T., Kwon, H., Park, Y. N., Kwon, T.-H., Hong, M., Choi, K., Ham, J., & Kim, Y. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01444-x · Cited by 13
Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line – Indian consensus statement update
Prabhash, K. (2019) · South Asian Journal of Cancer · doi:10.4103/sajc.sajc_227_18 · Cited by 13
Renal Effects of Crizotinib in Patients With ALK-Positive Advanced NSCLC
Camidge, D. R., Kim, E. E., Usari, T., Polli, A., Lewis, I., & Wilner, K. D. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.02.015 · Cited by 13
Self-citation
Clinical characteristics and risk factors of drug‐induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis
Koshikawa, K., Terada, J., Abe, M., Iwasawa, S., Sakayori, M., Yoshioka, K., Hirasawa, Y., Kasai, H., Kawasaki, Y., Tsushima, K., et al. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13416 · Cited by 13
Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?
Schoenmaekers, J. J. A. O., Paats, M. S., Dingemans, A. C., & Hendriks, L. E. L. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-459 · Cited by 13
Effect of alectinib versus crizotinib on progression-free survival, central nervous system efficacy and adverse events in ALK-positive non-small cell lung cancer: a systematic review and meta-analysis
Yang, Y., Xiang, Z.-J., Yang, J.-H., Wang, W., & Xiang, R. (2020) · Annals of Palliative Medicine · doi:10.21037/apm-19-643 · Cited by 13
Detailed structural study of cyclic anticancer drug Lorlatinib: spectroscopic and stereostructure investigation (IR, ECD and NMR) using density functional theory approach
Jiang, S., Jin, Y., Yan, R., & Wang, Z. (2020) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2020.129295 · Cited by 13
Lorlatinib in ALK-Rearranged Lung Cancer
Kuang, S., & Leighl, N. B. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.017 · Cited by 13
Case Report: A Case Report of a Histological Transformation of ALK-Rearranged Adenocarcinoma With High Expression of PD-L1 to Squamous Cell Carcinoma After Treatment With Alectinib
Zhang, Y., Qin, Y., Xu, H., Yao, Q., Gao, Y., Feng, Y., & Ren, J. (2021) · Pathology & Oncology Research · doi:10.3389/pore.2021.637745 · Cited by 13
Metastatic Large-Cell Neuroendocrine Lung Carcinoma With ALK Fusion Oncogene With Partial Response to Alectinib
Leblanc, A., Owen, S. P., Fiset, P., Corredor, A. L. G., Isenberg, J., & Bouganim, N. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00348 · Cited by 13
Combining Radiation Therapy with ALK Inhibitors in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer (NSCLC): A Clinical and Preclinical Overview
Antoni, D., Burckel, H., & Noël, G. (2021) · Cancers · doi:10.3390/cancers13102394 · Cited by 13
Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer
Abdayem, P., & Planchard, D. (2021) · European Respiratory Review · doi:10.1183/16000617.0294-2020 · Cited by 14
Clinicopathological features and resistance mechanisms in HIP1‐ALK ‐rearranged lung cancer: A multicenter study
Kang, J., Deng, Q., Peng, K., Li, P., Zhu, B. T., Wang, P., Chu, X., Zhong, W., Chen, H., Wang, W., et al. (2021) · Genes Chromosomes and Cancer · doi:10.1002/gcc.23005 · Cited by 13
Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas
Hsu, R. C., Baca, Y., Xiu, J., Wang, R., Bodor, J. N., Kim, C., Khan, H., Mamdani, H. M., Nagasaka, M., Puri, S., et al. (2021) · Oncotarget · doi:10.18632/oncotarget.28132 · Cited by 13
Safety and efficacy of endobronchial ultrasound‐guided transbronchial needle aspiration ( EBUS‐TBNA ) for patients aged 80 years and older
Niwa, H., Oki, M., Ishii, Y., Torii, A., Yamada, A., Shinohara, Y., Kogure, Y., & Saka, H. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14454 · Cited by 13
Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer
Hu, Y. W., Ren, S., Wang, R., Han, W., Xiao, P., Wang, L., Yu, F., & Liu, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.816683 · Cited by 13
Pan‐HER inhibitors overcome lorlatinib resistance caused by NRG1 / HER3 activation in ALK ‐rearranged lung cancer
Taniguchi, H., Akagi, K., Dotsu, Y., Yamada, T., Ono, S., Imamura, E., Gyotoku, H., Takemoto, S., Yamaguchi, H., Sen, T., et al. (2022) · Cancer Science · doi:10.1111/cas.15579 · Cited by 13
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer
Ricciuti, B., Mira, A., Andrini, E., Scaparone, P., Michelina, S. V., Pecci, F., Cantini, L., Giglio, A. D., Lamberti, G., Ambrogio, C., et al. (2022) · Drugs in Context · doi:10.7573/dic.2022-7-4 · Cited by 14
Clinical perspectives on serum tumor marker use in predicting prognosis and treatment response in advanced non-small cell lung cancer
Buma, A. I. G., Schuurbiers, M. M. F., van Rossum, H. H., & van den Heuvel, M. M. (2023) · Tumor Biology · doi:10.3233/tub-220034 · Cited by 13
Biology and impact of lineage plasticity in ALK-positive NSCLC: a narrative review
Meador, C. B., & Piotrowska, Z. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-867 · Cited by 14
Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?
Spitaleri, G., Aliaga, P. T., Attili, I., Signore, E. D., Corvaja, C., Corti, C., Crimini, E., Passaro, A., & de Marinis, F. (2023) · Current Oncology · doi:10.3390/curroncol30050384 · Cited by 14
Case report: continued treatment with alectinib is possible for patients with lung adenocarcinoma with drug-induced interstitial lung disease
Nitawaki, T., Sakata, Y., Kawamura, K., & Ichikado, K. (2017) · BMC Pulmonary Medicine · doi:10.1186/s12890-017-0519-y · Cited by 13
Progress in Radiotherapy for Regional and Oligometastatic Disease in 2017
Senan, S., Rusthoven, C. G., Slotman, B. J., & Siva, S. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.02.001 · Cited by 13
Current views on molecularly targeted therapy for lung cancer – a review of literature from the last five years
Rybarczyk-Kasiuchnicz, A., & Ramlau, R. (2018) · Polish Journal of Cardio-Thoracic Surgery · doi:10.5114/kitp.2018.76478 · Cited by 14
Efficacy and safety of crizotinib in patients with anaplastic lymphoma kinase-positive advanced-stage non-small-cell lung cancer
Mohieldin, A., Rasmy, A. A., Ashour, M., Al-Nassar, M., Ali, R. H., & El-Enezi, F. G. (2018) · Cancer Management and Research · doi:10.2147/cmar.s173084 · Cited by 13
Central Nervous System Cancers
Nath, S. K., Trifiletti, D. M., Zaorsky, N. G., & Rusthoven, C. G. (2019) · Springer eBooks · doi:10.1007/978-3-319-96809-4_3 · Cited by 14
Primary Resistance to Alectinib Was Lost after Bevacizumab Combined Chemotherapy in ALK-Rearranged Lung Adenocarcinoma
Nakasuka, T., Ichihara, E., Makimoto, G., Maeda, Y., & Kiura, K. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.03.009 · Cited by 13
Administration of docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte colony-stimulating factor for pretreated non-small cell lung cancer: a phase II study
Kasahara, N., Sunaga, N., Kuwako, T., Naruse, I., Imai, H., Jingu, A., Tsukagoshi, Y., Masuda, T., Kitahara, S., Tsurumaki, H., et al. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05317-z · Cited by 13
Neurologic complications of lung cancer
Sands, J. M., Daly, M. E., & Lee, E. Q. (2020) · Cancer · doi:10.1002/cncr.32772 · Cited by 13
Evaluating entrectinib as a treatment option for non-small cell lung cancer
Lee, J., Park, S., Jung, H. A., Sun, J., Lee, S., Ahn, J. S., Park, K., & Ahn, M. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1798932 · Cited by 13
Self-citation
ALK Inhibitors Do Not Increase Sensitivity to Radiation in EML4-ALK Non-small Cell Lung Cancer
FLESCHUTZ, K., Walter, L. M., Leistner, R., & Heinzerling, L. (2020) · Anticancer Research · doi:10.21873/anticanres.14497 · Cited by 14
The Clinical Impact of Capmatinib in the Treatment of Advanced Non–Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification
Choi, W., Park, S.-Y., Lee, Y., Lim, K. Y., Park, M., Lee, G. K., & Han, J. (2021) · Cancer Research and Treatment · doi:10.4143/crt.2020.1331 · Cited by 13
Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib
Ji, J., Mitra, A., Camidge, D. R., & Riess, J. W. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.04.008 · Cited by 13
Self-citation
Treatment of ALK‐rearranged non‐small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context
Itchins, M., Chia, P. L., Hayes, S. A., Howell, V., Gill, A. J., Cooper, W. A., John, T., Mitchell, P. L. R., Millward, M., Clarke, S. J., et al. (2017) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12754 · Cited by 13
ALK testing methods: is there a winner or loser?
Kozuma, Y., Toyokawa, G., & Seto, T. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1562343 · Cited by 13
Lurasidone Sensitizes Cancer Cells to Osimertinib by Inducing Autophagy and Reduction of Survivin
Suzuki, S., Yamamoto, M., Sanomachi, T., Togashi, K., Seino, S., Sugai, A., Yoshioka, T., Okada, M., & Kitanaka, C. (2021) · Anticancer Research · doi:10.21873/anticanres.15237 · Cited by 12
Anaplastic lymphoma kinase rearrangement prevalence in patients with advanced non-small cell lung cancer in the United States - retrospective real world data
Allen, T. C., Xiao, Y., Yang, B., Croix, D., Abraham, A., Redpath, S., Engstrom-Melynk, J., Shah, R. A., Madala, J., & Bernicker, E. (2021) · Oncotarget · doi:10.18632/oncotarget.28114 · Cited by 12
Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials
Gettinger, S. N., Huber, R. M., Kim, D., Bazhenova, L. A., Hansen, K. H., Tiseo, M., Langer, C. J., Rodríguez, L. G. P.-A., West, H., Reckamp, K. L., et al. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100385 · Cited by 12
Self-citation
Current status and challenges of immunotherapy in ALK rearranged NSCLC
Qi, R., Yu, Y., Shen, M., Lv, D., & He, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1016869 · Cited by 12
Synergistic effects of immune checkpoint inhibitors in combination with stereotactic radiosurgery for patients with lung cancer and brain metastases: a propensity score–matched analysis
Yomo, S., Oda, K., & Oguchi, K. (2023) · Journal of neurosurgery · doi:10.3171/2023.4.jns2349 · Cited by 12
Marketing authorisations for unmet medical needs: A critical appraisal of regulatory pathways in the European Union
Manellari, S., Musazzi, U. M., Rocco, P., & Minghetti, P. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123193 · Cited by 12
MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling
Chen, N., Tyler, L. C., Le, A. T., Welsh, E. A., Fang, B., Elliott, A., Davies, K. D., Danhorn, T., Riely, G. J., Ladanyi, M., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0218 · Cited by 12
Insight into systematic development of ALK (anaplastic lymphoma kinase) inhibitors towards NSCLC treatment
Yadav, V., Reang, J., Vinita, Sharma, P. C., Sharma, K., Kumar, D., & Tonk, R. K. (2024) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2024.100142 · Cited by 12
Real-World Treatment and Outcomes in ALK-Rearranged NSCLC: Results From a Large U.S.-Based Database
Chazan, G., Franchini, F., Shah, R. A., Alexander, M., John, A. K., IJzerman, M. J., & Solomon, B. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100662 · Cited by 12
Comparative Efficacy and Safety of Lorlatinib Versus Alectinib and Lorlatinib Versus Brigatinib for ALK-Positive Advanced/Metastatic NSCLC: Matching-Adjusted Indirect Comparisons
Garcia, C. A., Abrahami, D., Polli, A., Chu, H., Chandler, C., Tan, M., Kelton, J. M., Thomaidou, D., & Bauer, T. M. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.08.003 · Cited by 12
Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study
Tibau, A., Hwang, T. J., Avorn, J., & Kesselheim, A. S. (2024) · BMJ · doi:10.1136/bmj-2023-079126 · Cited by 13

Authors: Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., Zeaiter, A., Mitry, E., Golding, S., Balas, B., Noe, J., Morcos, P. N., & Mok, T.
Affiliations: F. Hoffmann-La Roche AG (CH)
ORCID: Peters, Solange
Camidge, D. Ross
Shaw, Alice T.
Gadgeel, Shirish
Ahn, Jin S.
Kim, Dong-Wan
Ou, Sai-Hong I.
Rosell, Rafael
Mitry, Emmanuel
Balas, Bogdana
Morcos, Peter N.
Mok, Tony
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2017-08-31
Volume: 377
Issue: 9
Pages: 829-838
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1704795
OpenAlex: W2624310346
Cited by: 2,527
References: 14
Citations by year: 2026: 173 · 2025: 216 · 2024: 260 · 2023: 270 · 2022: 306 · 2021: 336 · 2020: 327 · 2019: 276 · 2018: 277 · 2017: 82
FWCI: 218.03
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
SERVAL (Université de Lausanne) (publishedVersion, other-oa)
Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, public-domain)
IRIS (submittedVersion)
LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, public-domain)
Seoul National University Open Repository (Seoul National University) (submittedVersion)
Funders: Amgen
Bristol-Myers Squibb
Eli Lilly and Company
Pfizer
AstraZeneca
Ariad Pharmaceuticals
Celgene
F. Hoffmann-La Roche
Array BioPharma
Regeneron Pharmaceuticals
Taiho Pharmaceutical
Les Laboratories Pierre Fabre
Clovis Oncology
G1 Therapeutics
Eisai
Genentech
EMD Serono
Ignyta
Loxo Oncology
Foundation Medicine
Daiichi Sankyo Europe
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: alectinib, crizotinib, anaplastic lymphoma kinase, ALK-positive non-small cell lung cancer, ALK inhibitors, progression-free survival, CNS progression, central nervous system metastasis, objective response rate, overall survival, first-line therapy, targeted therapy, head-to-head comparison
MeSH terms: Crizotinib, Anaplastic Lymphoma Kinase, Adult, Aged, 80 and over, Animals, Antineoplastic Agents, Carbazoles, Carcinoma, Non-Small-Cell Lung, Female, Follow-Up Studies, Humans, Lung Neoplasms, Male, Middle Aged, Piperidines, Pyrazoles, Pyridines, Central Nervous System Neoplasms, Disease-Free Survival, Receptor Protein-Tyrosine Kinases, Protein Kinase Inhibitors, Kaplan-Meier Estimate, Young Adult, Intention to Treat Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks